Hongde Li

Dr. Hongde Li

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HYHaoran Yang
Haoran Yang
JLJunli Li
Junli Li
CSchengxiang song
chengxiang song
HLHongde Li
Hongde Li
QLQiang Luo
Qiang Luo
CMChen Mao
Chen Mao
Cardiovascular disease remains a leading cause of global mortality, with many unresolved issues in current clinical treatment strategies despite years of extensive research. Due to the great progress in nanotechnology and gene therapy in recent years, the emerging gene therapy based on nanocarriers has provided a promising therapeutic alternative for cardiovascular diseases. This review outlines the status of nanocarriers as vectors in gene therapy for cardiovascular diseases, including coronary heart disease, pulmonary hypertension, hypertension, and valvular heart disease. It discusses challenges and future prospects, aiming to support emerging clinical treatments. This review is the first to summarize gene therapy using nanocarriers for valvular heart disease, highlighting their potential in targeting challenging tissues.

29 October 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
HLHongde Li
Hongde Li
WLWei‐Ya Li
Wei‐Ya Li
JLJun‐Li Li
Jun‐Li Li
SPShi‐Qin Peng
Shi‐Qin Peng
YFYuan Feng
Yuan Feng
CMChen Mao
Chen Mao
Background: Currently, there is a lack of evidence for the long‐term bioprosthetic valve durability of patients with bicuspid aortic valve (BAV) following transcatheter aortic valve replacement (TAVR). Methods and Results: This study aimed to evaluate hemodynamic outcome, structural valve deterioration, and bioprosthetic valve failure during long‐term follow‐up after TAVR in patients with BAV versus patients with tricuspid aortic valve (TAV). Patients with BAV and TAV who underwent TAVR between 2012 and 2020, with echocardiography followed for at least 3 years, were included. Baseline characteristics, long‐term valve hemodynamic performance, structural valve deterioration, and bioprosthetic valve failure were compared between patients with BAV and TAV. A total of 170 patients with BAV and 145 patients with TAV were included. The mean duration of follow‐up for patients with BAV and TAV was 5.2±1.8 and 5.0±1.7 years. No significant differences were observed in the rates of structural valve deterioration and bioprosthetic valve failure between patients with BAV and TAV: structural valve deterioration, BAV 20 (11.8%) versus TAV 16 (11.0%) at last follow‐up ( P =0.861); bioprosthetic valve failure, BAV 3 (1.8%) versus TAV 7 (4.8%) at last follow‐up ( P =0.196). More than moderate intravalvular aortic regurgitation (1.8% versus 4.8%, P =0.196) and paravalvular leak (6.5% versus 3.4%, P =0.305) were rare in both patients with BAV and patients with TAV. Conclusions: This study indicated satisfactory long‐term valve durability of TAVR in patients with BAV. Comparable hemodynamic outcome, structural valve deterioration, and bioprosthetic valve failure could be achieved in patients with BAV and TAV during long‐term follow‐up after TAVR.

14 November 2025 in Science Advances
Verified
Journal Article
Open access
HWHong Wang
Hong Wang
YZYunming Zhang
Yunming Zhang
XLXu Liu
Xu Liu
HLHongde Li
Hongde Li
XCXi Chen
Xi Chen
WHWenqi Hu
Wenqi Hu
Magnetic soft structures are highly versatile in unstructured environments, making them attractive for minimally invasive medical devices. However, this versatility also renders them susceptible to unintended deformations under fluctuating magnetic fields. The challenge is further compounded by medical imaging limitations that hinder accurate estimation of device pose and shape and by anatomical boundaries that enforce misalignment with the field. Collectively, these factors can cause uncontrolled shape change and functional failure. Here, we focus on slender magnetic soft structures to investigate their stability under misaligned fields. Our anisotropic design, achieved through flexural joints, yields ~52-fold higher bending stiffness in the preferred direction and ~18-fold higher torsional stiffness than isotropic beams. This structure serves as a building block for stable spiral tentacles, helices, planar sheets, expandable devices, cubes, and three-dimensional tessellation. We validate robustness through wormlike self-propulsion, guidewire navigation with 30-fold lower insertion force, and capsule peristaltic locomotion, advancing safer, more controllable devices.

20 October 2026 in Aging Cell
Verified
Journal Article
Open access
YZYaoyu Zhang
Yaoyu Zhang
JZJialiang Zhang
Jialiang Zhang
YXYanjiani Xu
Yanjiani Xu
WLWenhua Lei
Wenhua Lei
FXFei Xu
Fei Xu
CMChen Mao
Chen Mao
Calcific aortic valve disease (CAVD) is an age‐associated valvular disorder in which calcification expands from discrete foci into adjacent tissue. We investigated whether mitochondrial‐derived vesicles (MDVs) released by human valvular interstitial cells (hVICs) exert pro‐calcific effects on recipient cells and how MDV release is regulated. Using ex vivo hemodynamic perfusion of human CAVD tissue, multi‐omics profiling, live‐cell single‐organelle tracking, MDV transfer assays, and in vivo Gas6 deletion, we found that calcifying hVICs hypersecreted MDVs that exerted pro‐calcific effects in recipient hVICs. High‐resolution imaging showed that mitochondria remodeled into donut‐shaped structures under pro‐osteogenic conditions; these structures served as physical platforms for MDV budding. Human CAVD valve tissues and hVICs treated with pro‐osteogenic medium also exhibited senescence‐associated features. Multi‐omics profiling identified growth arrest‐specific 6 (Gas6), a senokine, among 36 concordantly upregulated candidates. Functional analyzes showed that Gas6 promoted terminal MDV scission while leaving donut‐shaped mitochondrial precursor formation intact. Mechanistically, Gas6 promoted intracellular Ca 2+ accumulation, calcium/calmodulin‐dependent protein kinase II (CaMKII) activation, and dynamin‐related protein 1 (DRP1) phosphorylation at Ser616, supporting a Ca 2+ –CaMKII–DRP1 axis that facilitates terminal MDV scission. Pharmacological inhibition of CaMKII or DRP1 reduced MDV hypersecretion and subsequent recipient‐cell calcification, and Gas6 deletion in vivo attenuated valvular stenosis, calcification, and fibrotic remodeling. These findings identify Gas6‐dependent terminal MDV scission as a mechanism contributing to the intercellular propagation of valvular calcification in a CAVD context characterized by senescence‐associated features.

1 January 2025 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
QLQing Li
Qing Li
CSChengxiang Song
Chengxiang Song
ZWZisong Wei
Zisong Wei
JLJunli Li
Junli Li
HZHao Zhou
Hao Zhou
CMChen Mao
Chen Mao
Objective: Calcific aortic valve disease (CAVD) is a progressive cardiovascular condition driven by the osteogenic differentiation of valve interstitial cells (VICs), with no effective drug therapies currently available. Hence, our objective is to investigate the impact of thrombospondin‐1 (TSP‐1) silencing on CAVD progression. Methods: In vitro experiments were employed using human primary VICs with TSP‐1 knockdown, cultured in osteogenic induction medium, and followed by analyses including western blot, alkaline phosphatase staining, alizarin red staining, immunofluorescence, and flow cytometry. In vivo experiments used two murine models of CAVD to determine the role of TSP‐1 silencing on aortic valve calcification. Results: We observed that silencing of TSP‐1 reduced the osteogenic differentiation of VICs. Subsequent experiments demonstrated that TSP‐1 knockdown suppressed nuclear factor‐ κ B (NF‐ κ B)–mediated inflammation during osteoblastic differentiation of VICs. Consistent findings were also observed in two murine models of CAVD. Conclusions: The present study has shown that TSP‐1 silencing could mitigate the development of CAVD by inhibiting NF‐ κ B‐mediated inflammation. We propose that targeting TSP‐1‐mediated NF‐ κ B pathway could provide a potential therapeutic method for treating CAVD.

21 October 2026 in Aging Cell
Verified
Journal Article
Open access
YZYaoyu Zhang
Yaoyu Zhang
JZJialiang Zhang
Jialiang Zhang
YXYanjiani Xu
Yanjiani Xu
WLWenhua Lei
Wenhua Lei
FXFei Xu
Fei Xu
CMChen Mao
Chen Mao